43
Participants
Start Date
August 31, 2001
Primary Completion Date
January 31, 2009
Study Completion Date
January 31, 2009
Didanosine (ddI)
Antiretroviral Didanosine (ddI) : 240 mg/m\^2 up to a maximum of 400 mg once daily
Efavirenz (EFV)
Antiretroviral For Age Group 1 Efavirenz (EFV): dose adjusted for body size and for Age Groups 2 and 3 Efavirenz (EFV): up to a maximum of 600 mg once daily as a capsule ot 720 mg as an oral solution
Emtricitabine (FTC)
Antiretroviral Emtricitabine (FTC): 6 mg/Kg up to a maximum of 200 mg once daily
Nyu Ny Nichd Crs, New York
SUNY Upstate Med. Univ., Dept. of Peds., Syracuse
Howard Univ. Washington DC NICHD CRS, Washington D.C.
Univ. of Florida Jacksonville NICHD CRS, Jacksonville
Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami
Texas Children's Hosp. CRS, Houston
DUMC Ped. CRS, Durham
St. Jude/UTHSC CRS, Memphis
Chicago Children's CRS, Chicago
Univ. of Colorado Denver NICHD CRS, Aurora
UCSF Pediatric AIDS CRS, San Francisco
UCSD Maternal, Child, and Adolescent HIV CRS, San Diego
Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago
Harlem Hosp. Ctr. NY NICHD CRS, New York
Children's Hosp. of Boston NICHD CRS, Boston
WNE Maternal Pediatric Adolescent AIDS CRS, Worcester
Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan
San Juan City Hosp. PR NICHD CRS, San Juan
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
National Institute of Allergy and Infectious Diseases (NIAID)
NIH